Cheryl Jones

Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study

Maria Corinna Palanca-Wessels, Myron S. Czuczman, Gilles Salles et al. · The Lancet Oncology · 2015 · 335 citations

Pharmacy, Immunology, Oncology +16

Cross-cultural differences in maternal evaluation of children's body shapes

Matthew Hodes, Cheryl Jones, Hugh Davies · International Journal of Eating Disorders · 1996 · 87 citations

Public Health, Child Health, Pediatrics +13

Impact of Perioperative Acute Kidney Injury as a Severity Index for Thirty-Day Readmission After Cardiac Surgery

Jeremiah R. Brown, Chirag R. Parikh, Cathy S. Ross et al. · The Annals of Thoracic Surgery · 2013 · 53 citations · Full text

Medicine, Perioperative Medicine, Surgery +13

A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors.

Patricia LoRusso, Geoffrey I. Shapiro, Shuchi S. Pandya et al. · Journal of Clinical Oncology · 2012 · 48 citations

Medicine, Pharmacokinetics, Pharmacology +16

Updated Results of a Phase II Randomized Study (ROMULUS) of Polatuzumab Vedotin or Pinatuzumab Vedotin Plus Rituximab in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Franck Morschhauser, Ian W. Flinn, Ranjana H. Advani et al. · Blood · 2014 · 34 citations

Medicine, Immunology, Pharmacotherapy +15